Dusigitumab
Lonigutamab
Istiratumab
Dalotuzumab
Ganitumab
Robatumumab
Xentuzumab
Teprotumumab
Cixutumumab
Figitumumab
Veligrotug
IGF-I (30-41) (TFA)
IGF-I (24-41) (TFA)
Chimaphilin
AZ7550
AZ7550 hydrochloride
IGF-1R inhibitor-2
AG 538
AZ12253801
IGF-1R inhibitor-3